IL1B and cancer: HCV-infected patients with HBV reactivation during DAA therapy had remarkably lower IL-1β levels than did other HCV-infected patients, demonstrating the mechanical insight of de novo HBV reactivation during DAA therapy and different mechanisms of de novo HBV reactivation between anti-cancer therapy/immunosuppressive therapy and DAAs.